The main objective of this trial is to compare the effectiveness of a newer supraglottic airway method (the i-Gel), compared to current airway management practice in out-of-hospital cardiac arrests treated by Norwegian ambulance services.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
550
I-Gel supraglottic airway device
Laryngeal tube, endotracheal tube, bag-mask-ventilation
Haukeland University Hospital
Bergen, Norway
Innlandet Sykehus HF
Brumunddal, Norway
Helse Fonna HF
Haugesund, Norway
Ambulanse Midt-Norge HF
Trondheim, Norway
ventilation success
ventilation success defined as successful insertion of device with visible chest movement with each ventilation, audible air passage on auscultation, and ETCO2 confirmation (if available) of tube placement
Time frame: up to 24 hours
survival to hospital discharge / 30-day survival
Time frame: up to 30 days
levels of ETCO2 related to the presence and quality of bystander CPR
Time frame: up to 24 hours
cerebral function assessed by Glascow Outcome Score at discharge from hospital
Time frame: participants will be followed for the duration of hospital stay, an expected average of 4 weeks
insertion related complications
Time frame: up to 24 hours
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.